Bicycle Therapeutics Limited
Meditrina Building
Babraham Research Campus
Cambridge
CB22 3AT
United Kingdom
Tel: 44-0-1223-497-390
Fax: 44-0-7798-791-337
Website: http://www.bicycletherapeutics.com/
182 articles about Bicycle Therapeutics Limited
-
Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting - April 2, 2019
4/2/2019
Bicycle Therapeutics announced that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research Annual Meeting in Atlanta.
-
Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting
3/29/2019
Bicycle Therapeutics announced that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research Annual Meeting in Atlanta.
-
Bicycle Therapeutics Appoints Pierre Legault as New Director and Board Chairman - March 18, 2019
3/18/2019
Bicycle Therapeutics announced the appointment of Pierre Legault, MBA, CPA, as a Director and Chairman of the Board of Directors.
-
Bicycle Therapeutics Appoints Pierre Legault as New Director and Board Chairman
3/18/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, announced the appointment of Pierre Legault, MBA, CPA, as a Director and Chairman of the Board of Directors.
-
Bicycle Therapeutics to Present on BT5528, a Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumors, at World ADC 2019
3/5/2019
Bicycle Therapeutics announced that Gavin Bennett, Ph.D., Bicycle’s Director of Preclinical Development and Project leader for BT5528, will present at the 9th Annual World ADC Conference in London.
-
BioSpace Movers and Shakers: Feb. 22
2/22/2019
Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more. -
Bicycle Therapeutics Strengthens Executive Team with Key Changes
2/20/2019
Bicycle Therapeutics announced several key changes to its executive team, including the appointment of Peter B. Leone as Chief Business Officer and the promotion of Lee Kalowski, Chief Financial Officer, to the role of U.S. President.
-
Bicycle Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference
11/21/2018
The presentation will take place at 8:10 a.m. ET on Tuesday, November 27, 2018.
-
Bicycle Therapeutics’ Founder Sir Gregory Winter to Deliver Keynote Address at the 2018 Protein and Antibody Engineering (PEGS) Summit Europe
11/12/2018
Additional company presentation will highlight preclinical research supporting the development of CD137 Bicycle® agonists as novel cancer immunotherapies
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
Bicycle Therapeutics Strengthens Leadership Team with Appointment of Phil Jeffrey, Ph.D., as SVP Pre-Clinical Development
11/1/2018
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles™) product platform, today announced the appointment of Phil Jeffrey, Ph.D., as Senior Vice President of Pre-Clinical Development.
-
Bicycle Therapeutics Announces Presentation at the Royal Society
10/17/2018
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles™) product platform, announced that Chief Executive Officer Kevin Lee, Ph.D., will give a presentation at the “Delivery of Novel Therapies in the 21st Century”
-
Bicycle Therapeutics’ Founder Sir Gregory Winter Awarded Nobel Prize in Chemistry
10/3/2018
Bicycle Therapeutics today announced that its founder and Board member, Sir Gregory Winter, has been awarded the Nobel Prize in chemistry for his work in developing phage display for the directed evolution of antibodies and peptides to produce new medicines.
-
Bicycle Therapeutics and Cancer Research UK Announce Presentation at 2018 American Society of Clinical Oncology Meeting
5/31/2018
Cancer Research UK and Bicycle Therapeutics announced a poster presentation at the 2018 Annual Meeting of the American Society of Clinical Oncology.
-
Bicycle Therapeutics Announces Formation of Scientific Advisory Board
5/31/2018
Members include experts in oncology, immunology, and drug discovery and development
-
Bicycle Therapeutics Announces Clinical Milestone & Expands Collaboration with ThromboGenics
5/25/2018
Phase 1 clinical study initiated evaluating THR-149 in diabetic macular edema (DME) Alliance extended to develop additional Bicycles for ophthalmology
-
Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca
5/24/2018
New programs added in respiratory and cardio-metabolic diseases
-
Bicycle Therapeutics Promotes Michael Skynner, Ph.D., to Chief Operating Officer
3/20/2018
Dr. Skynner has served as Bicycle’s Vice President of Operations and Discovery since January 2016.
-
Bicycle Therapeutics and Cancer Research UK Announce Initiation of First Clinical Study of a Bicyclic Peptide (Bicycle)
2/13/2018
Bicycle Therapeutics and Cancer Research UK announced today that the first patient has been dosed in their Phase I/IIa trial evaluating BT1718 in patients with advanced solid tumors.
-
Bicycle Therapeutics Secures an Innovate UK Grant to Develop the Next Generation of Antibiotics
1/4/2018
Bicycle Therapeutics announced today that it has been awarded a grant from Innovate UK, the UK’s innovation agency, to apply Bicycle technology to develop the next generation of novel antibiotics.